医学治疗对降低节奏诱导心肌病的风险的影响
Mahdi S Agha1, Christopher L Schaich2, Rishi Rikhi1
1Department of Cardiovascular Medicine Wake Forest University School of Medicine Winston-Salem NC USA.
Journal of the American Heart Association
|July 4, 2025
概括
ангиотензин转化酶抑制剂 (ACEI), ангиотензин受体阻断剂 (ARB) 和β-阻断剂 (BB) 可能降低节奏诱导心肌病 (PICM) 的风险. 这些药物与右心室节奏负担较高的患者中较低的PICM发病率有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 右上心室节奏可以导致节奏诱导心肌病 (PICM).
- 确定PICM的预防策略对于患者的治疗结果至关重要.
研究的目的:
- 调查ACEI,ARB和BB使用与PICM风险之间的关联.
- 为了评估这些药物的保护作用在患有高右心室节奏负担的患者.
主要方法:
- 对642名正常喷射率和完全心脏阻塞的患者进行了回顾性研究.
- 医学治疗组 (ACEI/ARB,BB或两者) 与对照组之间的PICM发病率的比较.
- 使用细灰分发危险模型进行分析.
主要成果:
- 在药物治疗组中,PICM发生在4.7%的患者中,对照组为7.0%.
- 调整后的分析显示,在药物治疗组中,PICM的风险显著降低 (HR,0.59).
- 组合疗法显示PICM的风险最低 (HR,0.46).
结论:
- 使用ACEI,ARB或BB与PICM的发病率降低有关.
- 这些药物为患有高节奏负担的患者提供了潜在的保护策略.
相关概念视频
Myocarditis III: Medical Management
17
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
17
Cardiomyopathy V: Interprofessional Care
38
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
38
Cardiomyopathy III: Hypertrophic Cardiomyopathy
61
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
61
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Heart Failure Drugs: Inotropic Agents
739
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
739
Mitral Stenosis III: Medical Management
28
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
28


